B2M and breast carcinoma: In this study, our results show that: (1) the expression of β2-M transcripts only demonstrate a 15.66% up-regulation in the breast cancer specimens, no significant difference in the four breast cancer molecular subtypes, and no significant correlations with age, clinical stage or lymph node metastasis.